BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McLornan DP, Pope JE, Gotlib J, Harrison CN. Current and future status of JAK inhibitors. Lancet 2021;398:803-16. [PMID: 34454676 DOI: 10.1016/S0140-6736(21)00438-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Xing Q, Zhang Z, Zhu B, Lin Q, Shen L, Li F, Xia Z, Zhao Z. Case Report: Treatment for steroid-refractory immune-related myocarditis with tofacitinib. Front Immunol 2022;13:944013. [DOI: 10.3389/fimmu.2022.944013] [Reference Citation Analysis]
2 Pellegrino R, Pellino G, Selvaggi L, Selvaggi F, Federico A, Romano M, Gravina AG. BNT162b2 mRNA COVID-19 vaccine is safe in a setting of patients on biologic therapy with inflammatory bowel diseases: a monocentric real-life study. Expert Rev Clin Pharmacol 2022. [PMID: 36047032 DOI: 10.1080/17512433.2022.2120466] [Reference Citation Analysis]
3 Mulvihill C, Fitzgerald K, O'Regan E, Healy CM, Leahy TR. Successful treatment of oral potentially malignant lesions with ruxolitinib in STAT3 gain-of-function disease. Oral Oncol 2022;132:106015. [PMID: 35809509 DOI: 10.1016/j.oraloncology.2022.106015] [Reference Citation Analysis]
4 Sideris N, Paschou E, Bakirtzi K, Kiritsi D, Papadimitriou I, Tsentemeidou A, Sotiriou E, Vakirlis E. New and Upcoming Topical Treatments for Atopic Dermatitis: A Review of the Literature. JCM 2022;11:4974. [DOI: 10.3390/jcm11174974] [Reference Citation Analysis]
5 Chen C, Yin Y, Shi G, Zhou Y, Shao S, Wei Y, Wu L, Zhang D, Sun L, Zhang T. A highly selective JAK3 inhibitor is developed for treating rheumatoid arthritis by suppressing γc cytokine-related JAK-STAT signal. Sci Adv 2022;8:eabo4363. [PMID: 35984890 DOI: 10.1126/sciadv.abo4363] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Luo R, Wang Y, Guo Q, Fan C, Jiang G, Wang L, Zou M, Wang T, Sun Y, Peng X. Andrographolide attenuates Mycoplasma gallisepticum-induced inflammation and apoptosis by the JAK/PI3K/AKT signal pathway in the chicken lungs and primary alveolar type II epithelial cells. International Immunopharmacology 2022;109:108819. [DOI: 10.1016/j.intimp.2022.108819] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Shah P, Siddique A, Thakkar A, Gharat S, Godad A, Kale P, Doshi G. An update on novel therapeutic intervention in Rheumatoid arthritis. International Immunopharmacology 2022;109:108794. [DOI: 10.1016/j.intimp.2022.108794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Saha C, Harrison C. Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib. Expert Rev Hematol 2022. [PMID: 35787092 DOI: 10.1080/17474086.2022.2098105] [Reference Citation Analysis]
9 Wang J, Jiang M, Xiong A, Zhang L, Luo L, Liu Y, Liu S, Ran Q, Wu D, Xiong Y, He X, Leung EL, Li G. Integrated analysis of single-cell and bulk RNA sequencing reveals pro-fibrotic PLA2G7high macrophages in pulmonary fibrosis. Pharmacol Res 2022;182:106286. [PMID: 35662628 DOI: 10.1016/j.phrs.2022.106286] [Reference Citation Analysis]
10 Li Y, Meng D, Xie J, Li R, Wang Z, Li J, Mou L, Deng X, Deng P. Design of Rational JAK3 Inhibitors Based on the Parent Core Structure of 1,7-Dihydro-Dipyrrolo [2,3-b:3',2'-e] Pyridine. Int J Mol Sci 2022;23:5437. [PMID: 35628248 DOI: 10.3390/ijms23105437] [Reference Citation Analysis]
11 Benanti G, Dagna L, Campochiaro C. Lights and shadows on JAK inhibitors for Ankylosing Spondylitis. European Journal of Internal Medicine 2022. [DOI: 10.1016/j.ejim.2022.05.018] [Reference Citation Analysis]
12 Levy G, Guglielmelli P, Langmuir P, Constantinescu S. JAK inhibitors and COVID-19. J Immunother Cancer 2022;10:e002838. [PMID: 35459733 DOI: 10.1136/jitc-2021-002838] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Niedźwiedzka-Rystwej P, Majchrzak A, Kurkowska S, Małkowska P, Sierawska O, Hrynkiewicz R, Parczewski M. Immune Signature of COVID-19: In-Depth Reasons and Consequences of the Cytokine Storm. Int J Mol Sci 2022;23:4545. [PMID: 35562935 DOI: 10.3390/ijms23094545] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Galloway J, Atzeni F. JAK inhibitors: special issue foreword. Expert Rev Clin Immunol 2022;:1-2. [PMID: 35254191 DOI: 10.1080/1744666X.2022.2050596] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Nielsen OH, Boye TL, Chakravarti D, Gubatan J. Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease. Trends Pharmacol Sci 2022:S0165-6147(22)00032-3. [PMID: 35277286 DOI: 10.1016/j.tips.2022.02.008] [Reference Citation Analysis]
16 Huang Y, Zhang Z, Zhu L, Chen Y. Treatment of Progressive Nodular Histiocytosis With Baricitinib. JAMA Dermatol 2022. [PMID: 35044417 DOI: 10.1001/jamadermatol.2021.5579] [Reference Citation Analysis]
17 Qi F, Liu F, Gao L. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review. Front Immunol 2021;12:790125. [PMID: 34868078 DOI: 10.3389/fimmu.2021.790125] [Cited by in F6Publishing: 4] [Reference Citation Analysis]